Adverum Biotechnologies, Inc. (ADVM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1149852,
    "name": "Adverum Biotechnologies, Inc.",
    "stock_name": "Adverum Biotechnologies, Inc.",
    "full_name": "Adverum Biotechnologies, Inc.",
    "name_url": "stocks-analysis/adverum-biotechnologies-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.17",
    "chg": 0.01,
    "chgp": "0.24%",
    "dir": 1,
    "prev_price": "4.16",
    "mcapval": "74.28",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US00773U1088",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.75 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/adverum-biotechnologies-inc-1149852-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Adverum Biotechnologies Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/adverum-biotechnologies-forms-golden-cross-signaling-potential-bullish-breakout-3622651",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AdverumBiotechn_goldencross_3622651.png",
        "date": "2025-10-15 15:27:59",
        "description": "Adverum Biotechnologies, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has risen significantly today and shows a strong recovery trend over the past month, despite a challenging year-to-date performance and substantial long-term declines. Technical indicators suggest a positive outlook."
      },
      {
        "title": "Is Adverum Biotechnologies, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adverum-biotechnologies-inc-technically-bullish-or-bearish-3547391",
        "imagepath": "",
        "date": "2025-09-20 19:54:17",
        "description": "As of 5 September 2025, the technical trend for Adverum Biotechnologies, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven by daily moving averages indicating a mildly bearish position, while weekly indicators such as the Dow Theory and OBV also reflect a mildly bearish outlook. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is tempered by the bearish monthly Bollinger Bands and KST. \n\nIn terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -36.83% versus the S&P 500's 12.22%, and a one-year return of -57.80% compared to 17.14% for the index...."
      },
      {
        "title": "Is Adverum Biotechnologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adverum-biotechnologies-inc-overvalued-or-undervalued-3543775",
        "imagepath": "",
        "date": "2025-09-20 18:28:20",
        "description": "As of 4 November 2024, the valuation grade for Adverum Biotechnologies, Inc. has moved from does not qualify to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, given its high Price to Book Value of 2.24, an extremely low EV to EBIT of 0.11, and a negative EV to Sales ratio of -16.73. Compared to peers, Adverum's EV to EBITDA ratio of 0.11 is significantly lower than XOMA Corp.'s -22.9484 and Alimera Sciences, Inc.'s 27.2619, highlighting its relative underperformance.\n\nIn terms of stock performance, Adverum has faced substantial declines, with a year-to-date return of -36.83%, compared to a positive 12.22% for the S&P 500, and a staggering -97.62% over the past five years against a 96.61% gain for the index. This stark contrast reinforces the notion that Adverum is currently overvalued in the market...."
      }
    ],
    "total": 8,
    "sid": "1149852",
    "stock_news_url": "https://www.marketsmojo.com/news/adverum-biotechnologies-inc-1149852"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Adverum Biotechnologies Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-15 15:27:59

Adverum Biotechnologies, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has risen significantly today and shows a strong recovery trend over the past month, despite a challenging year-to-date performance and substantial long-term declines. Technical indicators suggest a positive outlook.

Is Adverum Biotechnologies, Inc. technically bullish or bearish?

2025-09-20 19:54:17

As of 5 September 2025, the technical trend for Adverum Biotechnologies, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven by daily moving averages indicating a mildly bearish position, while weekly indicators such as the Dow Theory and OBV also reflect a mildly bearish outlook. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is tempered by the bearish monthly Bollinger Bands and KST. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -36.83% versus the S&P 500's 12.22%, and a one-year return of -57.80% compared to 17.14% for the index....

Is Adverum Biotechnologies, Inc. overvalued or undervalued?

2025-09-20 18:28:20

As of 4 November 2024, the valuation grade for Adverum Biotechnologies, Inc. has moved from does not qualify to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, given its high Price to Book Value of 2.24, an extremely low EV to EBIT of 0.11, and a negative EV to Sales ratio of -16.73. Compared to peers, Adverum's EV to EBITDA ratio of 0.11 is significantly lower than XOMA Corp.'s -22.9484 and Alimera Sciences, Inc.'s 27.2619, highlighting its relative underperformance. In terms of stock performance, Adverum has faced substantial declines, with a year-to-date return of -36.83%, compared to a positive 12.22% for the S&P 500, and a staggering -97.62% over the past five years against a 96.61% gain for the index. This stark contrast reinforces the notion that Adverum is currently overvalued in the market....

View All News